Children’s Hospital of PhiladelphiaPI: Michele LambertODSH as a Countermeasure for Radiation-Induced Thrombocytopenia
Duke UniversityPI: Jun ChenA Novel Nanoparticle Platelet Analogue for Radiation-Induced Thrombocytopenia
University of Maryland School of MedicineThomas MacVittie, Ph.D.
University of North CarolinaMichael Jay, Ph.D.
SRI InternationalGita Shankar, Ph.D.
2010 CMCR Individual Project Descriptions (PDF)
Chandan Guha, M.D., Ph.D.Albert Einstein Medical CollegeStem Cell-Based Therapies for Mitigation of Acute Radiation Syndromes
David Brenner, Ph.D.Columbia University Medical CenterCenter for High-Throughput Minimally-Invasive Radiation
Harold Swartz, M.D., Ph.D.Dartmouth Medical SchoolPhysically-Based Biodosimetry for Triage after a Large Radiation Incident
Nelson Chao, M.D.Duke UniversityRadiation Countermeasures Center of Research Excellence
William McBride, Ph.D.University of CaliforniaUCLA Center for Biological Radiation Mitigators
Joel Greenberger, M.D.University of Pittsburgh Medical CenterMitochondrial Targeting against Radiation Damage
Jacqueline Williams, Ph.D.University of RochesterUniversity of Rochester Center for Medical Countermeasures against Radiation
2005 CMCR Individual Project Descriptions (PDF)
Columbia UniversityDavid Brenner, Ph.D.Center for High Throughput, Minimally Invasive, Radiation Biodosimetry
Dana-Farber Cancer InstituteAlan D’Andrea, M.D.Dana-Farber/Harvard Center for Medical Countermeasures Against Radiation
Duke University Medical CenterNelson Chao, M.D.Radiation Countermeasures Centers of Research Excellence (RadCCORE)
Fred Hutchinson Cancer Research CenterGeorge Georges, M.D.Radiation Dose-Dependent Interventions
Medical College of WisconsinJohn Moulder, Ph.D.Post-Irradiation Intervention to Mitigate and Treat Non-Hematological Injuries
University of California David Geffen School of MedicineWilliam McBride, Ph.D., D., Sci.UCLA Center for Biological Radioprotectors
University of PittsburghJoel Greenberger, M.D.Mitochondrial Targeting Against Radiation Damage
University of Rochester Medical CenterPaul Okunieff, M.D.Center for Biophysical Assessment and Risk Management Following Radiation
Cleveland Biolabs, Inc.Andrei Gudkov, Ph.D., D. Sci.Protecting the immune system by modulators of p53 and NF-kB
Fred Hutchinson Cancer Research CenterGeorge Georges, M.D.Cytokines for immune protection from acute irradiation
University of Illinois at ChicagoAmelia Bartholomew, M.D.Restoring hematopoiesis following radiation injury
University of Maryland Greenebaum Cancer CenterThomas MacVittie, Ph.D.Immune reconstitution in non-human primates
Pacific Northwest National LaboratoryTatiana G. Levitskaia, PhD.Biomaterials as Decorporation Agents for Radionuclides
Pacific Northwest National LaboratoryCharles Timchalk, Ph.D.Development of Selective Nanoporous Sorbents for Radionuclide Decorporation
University of California/Lawrence Berkeley National LaboratoryKenneth N. Raymond, Ph.D.Biomimetic Lanthanide & Actinide Decorporation Agents: Preclinical Development
University of FloridaRaymond J. Bergeron, Ph.D.Desferrithiocin Analogue Actinide Decorporation Agents
University of Utah School of MedicineScott C. Miller, Ph.D.Amphipathic Oral Chelators and Radionuclide Contamination
Children's Hospital and Research Center at OaklandJulie D. Saba, M.D., Ph.D.Endogenous sphingosine-1-phosphate as a radioprotector of intestinal tissues
Duke UniversityDavid Kirsch, M.D., Ph.D.Dissecting the Mechanism of the GI Syndrome to Restore GI Function after Radiation
Fred Hutchinson Cancer Research CenterGeorge Georges, M.D.Improving Gastrointestinal Recovery after Radiation
RxBio, Inc.Wenlin Deng, M.D., Ph.D.Radioprotective/Radiomitigating Efficacy of Rx100 in the Gastrointestinal Tract
University of Medicine and Dentistry of New JerseyAlexey G. Ryazanov, Ph.D.Development of New Drugs that Protect Gastrointestinal Tract from Radiation
University of Medicine and Dentistry of New JerseyRoger Howell, Ph.D.Protection against radiation-induced damage to intestinal nutrient transport
University of Arkansas for Medical SciencesAlexander Burnett, M.D.Oral Interleukin 11 as a Countermeasure against Radiation Injury to Gut
University of Maryland, BaltimoreTerez Shea-Donohue, Ph.D.Novel Therapy for Post-Irradiation Insult to Gut Mucosa in Non-Human Primates>
University of Illinois at Chicago Amelia M. Bartholomew, M.D.Parathyroid Hormone in Prevention and Mitigation of Thrombocytopenia
Fred Hutchinson Cancer Research CenterGeorge Georges, M.D.Improving Platelet Recovery After Radiation
Cleveland Biolabs, Inc.Andrei V. Gudkov, Ph.D., D.Sci.Protectan CBLB502
Cellerant Therapeutics, Inc.Holger Karsunky, Ph.D.Development of ex vivo Expanded Megakaryocyte Progenitors for Platelet Recovery Following Irradiation
University of Pennsylvania School of MedicineMortimer Poncz, M.D.Megakaryocyte Chemokines & Post-Irradiation Thrombocytopenia
Weill Cornell Medical CollegeReconstitution of thrombopoiesis by angiogenic factors
University of Southern CaliforniaKathleen E. Rodgers, Ph.D.A(1-7)-Mediated Mitigation of Radiation Induced Thrombocytopenia
University of Pittsburgh Medical CenterLouis Falo, M.D., Ph.D.Novel Cutaneous Radiation Injury Countermeasures
University of California, Los AngelesWilliam McBride, Ph.D.Mesenchymal Stem Cells To Mitigate and Treat Cutaneous Injury Following Radiation
University of Massachusetts Medical SchoolKenneth Rock, M.D.Mitigating radiodermatitis by blocking IL-1-dependent neutrophilic inflammation
University of Southern CaliforniaKathleen E. Rodgers, Ph.D.NorLeu3-A(1-7): Enhanced Recovery of Radiation Burns
Medical College of WisconsinMeetha Medhora, Ph.D.Development of ACE Inhibitor as Countermeasure for Radiation-Induced Lung Injury
Fred Hutchinson Cancer Research CenterRichard Nash, M.D.Mitigation of Radiation-Induced Lung Injury in the Dog Model
Parion SciencesKarl Donn, Ph.D.Novel Therapies for Enhancing Clearance of Inhaled Radioactive Particles
University of RochesterJacqueline Williams, Ph.D.Combined Target Therapy for the Pulmonary Syndrome
Emory UniversityHui-Kuo Shu & Hyunsuk ShimBlockade of the SDF-1/CXCR4 axis as a novel strategy for mitigating radiation-induced lung damage
Massachusetts General HospitalKathryn Held, Leo Gerweck & Mark PoznanskyNovel agents for mitigation of radiation-induced pulmonary injury
University of PennsylvaniaMelpo Christofidou-SolomidouMitigation of Radiation Pneumonopathy By Lignan Action
University of FloridaShanmin YangA Novel Mitigator for Radiation Lung Injury
Duke UniversityZeljko VujaskovicAntioxidant Mimetic as a Mitigator of Radiation Induced Lung Injury
Battelle Pacific Northwest LaboratoriesR. Shane Addleman, D.Sci.Rapid Assay for Internalized Radionuclides with Advanced Materials and Methods
Colorado State UniversitySusan M. Bailey, Ph.D.Chromosomal alterations in basic mechanisms of radiation injury
Medical College of WisconsinJohn Baker, Ph.D.Radiation injury to the heart
University of PittsburghNegative Effects of Irradiated Hosts on Transplanted Hematopoietic Stem Cells
Roswell Park Cancer InstituteAndrei V. Gudkov, Ph.D., D. Sci.Controlling Radiation Injury by TLR5 Agonists
Duke UniversityDavid G. Kirsch, M.D., Ph.D.Mechanisms of Late Effects of Exposure to Radiation
University of RochesterJames Palis, M.D.Hematopoietic targets of radiation: identification and mitigation
Fred Hutchinson Cancer Research CenterAmanda G. Paulovich, M.D., Ph.D.Minimizing mass panic with saliva tests for radiation exposure
The University of Tennessee Health Science CenterGabor J. Tigyi, M.D., Ph.D.Analysis of Radiomitigative Cell Signaling
Memorial Sloan-Kettering Institute for Cancer ResearchMarcel R.M. van den Brink, M.D., Ph.D.Strategies to Enhance Lymphoid Recovery After Radiation-Induced Injury
Medical University of South CarolinaDaohong Zhou, M.D.Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury
Johns Hopkins UniversityShyam Biswal, Ph.D.Novel strategy to mitigate and treat radiation combined infection injury by targeting Nrf2
Duke UniversityNelson J. Chao, M.D.Skin Stem Cells in Combined Radiation Injury
University of California, San FranciscoJohn R. Fike, Ph.D.Combined radiation and traumatic injury affect hippocampal structure and function
The University of Tennessee Health Science CenterDuane D. Miller, Ph.D.; M. Waleed Gaber, Ph.D (Baylor College of Medicine)Treatment with KZ-41 and OTP promotes wound healing in a radiation combined injury
Uniformed Services University for Health SciencesJuliann G. Kiang, Ph.D.Ciprofloxacin enhances DNA repair capacity after radiation combined injury
Loyola University of ChicagoElizabeth J. Kovacs, Ph.D.Inflammatory response after combined insult of radiation and burn injury
Brigham and Women's HospitalJames A. Lederer, Ph.D.Immunological Complications of Radiation Combined Injury
University of California, DavisDavid M. Rocke, Ph.D., and R. Rivkah Isseroff, M.D.Molecular mechanisms and novel therapeutic approaches to combined radiation and burn
Feinstein Institute for Medical ResearchPing Wang, M.D.Radiation Combined Injury: Mechanisms and Therapeutic Approaches
Blood Center of WisconsinHartmut Weiler, Ph.D.Activated Protein C for Treatment of Radiation Combined Injury
Albert Einstein College of MedicineChandan GuhaStem Cell Based Therapy For Radiation Induced Gastrointestinal Syndrome
Cleveland Biolabs, Inc.Andrei Gudkov, Ph.D., D. Sci.Mechanisms of mitigation of radiation damage of GI tract by Protectan CBLB502
University of California, BerkeleyKenneth Raymond, Ph.D.Biomimetic Actinide Decorporation: Characterization and Preclinical Development
University of FloridaLurong ZhangBioactive Peptides for Mitigation of AGS and Acute Radiation Injury
The University of Tennessee Health Science CenterGabor Tigyi, M.D., Ph.D.Preclinical Development of a GI Radiation Countermeasure
University of Texas Medical Branch, GalvestonFujio SuzukiA gene therapy for bacterial translocation in mice with whole body irradiation
Dana-Farber Cancer InstituteDipanjan Chowdhury, Ph.D.Serum microRNA as biomarker for radiation injury to lung and hematopoietic cells
Fred Hutchinson Cancer Research CenterAmanda Paulovich, M.D., Ph.D.Discovering tissue-specific biomarkers of radiation injury in SILAC-labeled mice
Georgetown UniversityAlbert Fornace, M.D.Metabolomic biomarkers and instrumentation for assessment of radiation injury
The Medical College of WisconsinMeetha Medhora, Ph.D.Innovative biomarkers to predict radiation lung injury
University of California Los AngelesJulian Whitelegge, Ph.D.Organ-specific NRF2-mediated protein signatures of radiation exposure & tissue damage
University of RochesterIdentification of biomarkers for late radiation lung damage
Bolder Biotechnology, Inc.George Cox, PhDLong-acting growth factors for treating the acute and long term effects of lethal irradiation
Brigham and Women’s HospitalJames Lederer, PhDRestoring immune function following radiation injuries by TLR9 agonist treatment
Duke UniversityJohn Chute, MDEpidermal growth factor mitigates radiation-induced hematopoietic failure
Medical College of WisconsinMeetha Medhora, PhDDevelopment of lisinopril for post-exposure mitigation of late effects from a radiation exposure
University of Maryland, BaltimoreZeljko Vujaskovic, MD, PhDMitigation of radiation-induced pulmonary injury with Nrf2 activator
University of Rochester Medical CenterJames Palis, MDPGE2 mitigation of acute and late radiation injury
The University of Tennessee Health Science CenterGabor Tigyi, MD, PhDIND-enabling preclinical development of a new radiomitigator
University of Texas Medical Branch, GalvestonFujio Suzuki, PhDCCL1 gene therapy to inhibit bacterial translocation in acute radiation syndromes
Co-funded between the National Institute of Diabetes and Digestive and Kidney Diseases and NIAID, the mission of this consortium is to advance the understanding of intestinal epithelial stem cell biology during development, homeostasis, regeneration and disease.
Baylor College of MedicinePI: Mary EstesIntestinal Stem Cell Response to Infection
Cincinnati Children’s Hospital Medical CenterPI(s): Michael Helmrath, Noah Schroyer, James WellsInvestigation of Regional Identity in Human Intestinal Stem Cells
City of HopePI: Joyce NilandIntestinal Stem Cell Consortium Coordinating Center
Columbia University Medical CenterPI(s): Timothy Wang, Chandan GuhaDifferentiating Radio-Sensitivities among Intestinal Stem Cell Pools
Dana-Farber Cancer InstitutePI: Ramesh ShivdasaniChromatin and Transcriptional Control of LGR5+ Crypt Base Stem Cells
Stanford UniversityPI: Calvin KuoRegulation of Actively Proliferating and Quiescent Intestinal Stem Cells
Stowers InstitutePI: Linheng LiCellular, Molecular, and Functional Characterization of Quiescent/Active Intestinal Stem Cells
University of California, Los AngelesPI(s): Martin Martin, James Dunn, Matthias StelznerIntestinal Stem Cell Culture and Entero-Endocrine Lineage Development
University of California San FranciscoPI: Ophir KleinRegulation of Distinct Pools of Intestinal Stem Cells
University of MichiganPI: Jason SpenceMechanisms of Fetal Intestinal Stem Cell Regulation and Maturation
Established in 2005, the Inter-Agency Agreement between NIAID and the Armed Forces Radiobiology Research Institute (AFRRI) funds research in several areas related to the challenges encountered following radiological or nuclear events. These include: 1) Screen countermeasures to prevent, mitigate/ treat radiation injuries; 2) Automation of dicentric assay; 3) Develop animal model, study mechanism, and screen countermeasures to mitigate/treat radiation combined injury; 4) Develop animal model, study mechanism, and screen countermeasures to mitigate/treat gamma/neutron mixed field injury; 5) Develop Gottingen Minipig as a Model for Acute Radiation Syndrome.
The NIAID-funded AFRRI screening program has performed toxicity studies, dose optimization, time optimization for post exposure, optimum route of administration and efficacy of post exposure (24 hours and beyond) administration of 55 single drugs and 3 combinations on survival in CD2F1 male mice at LD90/30 and LD70/30 doses. One of the promising drugs is being evaluated for post- exposure efficacy in non-human primate model. NIAID-funded work at AFFRI has automated dicentric sample processing and scoring with a throughput of approximately 1,000 samples per day. In addition, AFRRI has developed and characterized rodent model for radiation+wound and radiation+burn combined injury as well as neutron (65 percent) + gamma (35 percent) mixed field injury, and efficacy evaluation of several potential countermeasures in these animal models is on going. Also, AFRRI has developed and characterized Gottingen Minipig as a model for acute radiation syndrome.
NIAID and the National Cancer Institute (NCI) are cooperating on specific research ranging from identification, characterization, and validation of safe and effective radiation/nuclear medical countermeasures, development of biology-based diagnostic assays or biomarkers to assess cellular and tissue damage following exposure to ionizing radiation and addressing other scientific areas with strong programmatic relevance, such as radiation epidemiology and radionuclide decorporation.
The following principal investigators within intramural NCI have projects being funded by this intramural opportunity within the NIAID Radiation/Nuclear Countermeasures Program:
Dr. Amy Berrington de González
Dr. Kiyohiko Mabuchi
Dr. Steven Simon
Dr. William Bonner
Dr. Martin Brechbiel
Dr. Deborah Citrin
Dr. Frank Gonzalez
Dr. James Mitchell
Scientific accomplishments for this program include
Finding of a large bystander effect in 3-dimensional skin and airway radiation exposure models. This has implications for effects of partial body irradiations or inhomogeneous exposures.
Demonstration of a clear separation in metabolomic signatures between sham and irradiated in vitro samples, with little variation between sham-irradiated cells, and identification of several candidate metabolomic markers for radiation exposure.
Analysis of I-131 biokinetic data from 140 patients treated with I-131 for hyperthyroid, EPR analysis of 103 teeth from Semipalatinsk, Kazakhstan, populations exposed to radiation and testing of a novel biodosimetry system based on optically stimulated luminescence (OSL).
Synthesis of 8 nitroxide analogs and irradiation of 1,275 mice (2 strains) in order to evaluate the efficacy of Tempol food in minimizing radiation-induced carcinogenesis.
NIAID and the National Institute on Aging (NIA) are cooperating on specific research and development projects to benefit both Institutes’ goals of advancing the study of immunesenescence from the natural process of aging and radiation exposure and its amelioration in prevention and intervention therapies. Awarded in September 2009, the following laboratories within intramural NIA are being funded:
Dr. Louis Rezanka (Laboratory of Immunology)
Dr. Nan-Ping Weng (Laboratory of Immunology)
Dr. Rui-Ping Xiao (Laboratory of Cardiovascular Science)
These research projects, funded at the end of FY 09, focus on how ionizing radiation and natural aging affect a person’s ability to respond to vaccination and the ability of the immune system to respond to vaccination and cause inflammation, which is a hallmark of immune aging.
RFA-AI-14-055: Centers for Medical Countermeasures against Radiation Consortium (U19) - Receipt date Oct. 3, 2014
RFA-DK-13-012: Intestinal Stem Cell Consortium Research Projects (U01) (co-funded by NIAID) – Receipt date Oct. 21, 2013.
PA-12-044: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44])
PAR-09-027: Product development program to provide synthesis, scale- up production, analytical methods development, PK/ADME, formulation development, manufacture of Phase I supplies, GLP Tox, and product development planning. National Institutes of Health Rapid Access to Interventional Development (NIH-RAID Program) (X01).
HHS-NIH-NIAID(AI)-RFI-13-057: Request for Information – Radiation/Nuclear Countermeasure Product Development Support Services. Response Date Aug. 19, 2013.
FY2014 NIH and CDC SBIR contract solicitation (PHS-2014-1) – Topic 332: Development of Radiation Modulators for Use during Radiotherapy. Deadline for Receipt: Nov. 13, 2013.
BAA-13-100-SOL-00013: Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures for BARDA. Posted July 31, 2013
BAA-13-100-SOL-00014: Science and Technology Platforms Applied to Medical Countermeasure Development (Innovations) for BARDA. Posted July 31, 2013
RFP-NIAID-DAIT-NIHAI2014005: Radiation/Nuclear Medical Countermeasure (MCM) Product Development Support Services. Response Date – Dec. 1, 2014
RFP-BARDA-10-100-SOL-00025: BARDA Animal Model Development of Chemical, Biological, Radiological, and Nuclear; Influenza; and Emerging Infectious Disease Medical Countermeasures
Columbia CMCR Pilot Project Funds Now Available! Submission deadline: March 14, 2014. Download Submission Instructions (PDF)
Rochester CMCR Pilot Project Funds Now Available! Submission deadline: White Paper - Feb. 3, 2014 Download Submission Instructions (PDF)
NIAID-RFI-NOT-AI-15-034: Request for Information (RFI): Development of Radiation/Nuclear Medical Countermeasures, Predictive Biomarkers, and Biodosimetry Devices. Due Date May 26, 2015.
Sources Sought Notice: Radiation/Nuclear Medical Countermeasure Product Development Support Services - HHS-NIH-NAID(AI)-SBSS-14-005. Due Date: April 4, 2014.
Request for Information (Department of the Army – Solicitation #W911QY-13-S-0003): Identification of Radiological Diagnostic Devices. Due Date: March 26, 2013.
DARPA-SN-13-24: Reducing Ionizing Radiation Risk (RFI). Receipt date April 2, 2013.
Request for Information: Joint Program Executive Office for Chemical and Biological Defense (CBMS-MITS), Department of Defense: Identification of a Physical Dosimetry or Biodosimeter as a Medical Radiation Countermeasure (MRADC) (responses due Jan. 28, 2012).
Mechanisms, Detection and Countermeasure Research and Development for Mixed-Field Radiation Exposure (responses due February 3, 2012)
NOT-AI-11-044 - Request for Information (RFI): Pediatric and Geriatric Animal Models and Medical Countermeasures Development for Mitigation and Treatment of Radiation Exposure from a Radiological or Nuclear Incident (response date July 19, 2011)
RFI-BARDA-08-21A: Physical and Biological Dosimetry Techniques and Devices Useful in Initial Triage After Radiologic and Nuclear Events. Issued by ASPR, OS, DHHS on May 20, 2008.
NOT-AI-07-033: Agents to Enhance Platelet Regeneration and Increase Survival following Radiation Exposure (Issued May 24, 2007).
NOT-AI-07-028: GLP Radionuclide Testing Facilities (Issued March 23, 2007).
Centers for Medical Countermeasures Against Radiation—Request for Information (Released April 9, 2004).
Neutropenia RFI Issued by HHS (Released Oct. 29, 2004).
RFA-AI-12-023: Development of Medical Countermeasures for Post-Exposure Mitigation/Treatment of Injuries Resulting from a Radiation/Nuclear Incident (U01)
RFA-AI-11-033: Predictive Biodosimetry: Discovery and Development of Biomarkers for Acute and Delayed Radiation Injuries (R01)
RFA-09-036: Centers for Medical Countermeasures Against Radiation (U19)
RFA-DK-08-010: Intestinal Stem Cell Consortium (U01) - Co-Funded by the NIAID Radiation/Nuclear Program. Receipt date: March 18, 2009.
NSBRI-RFA-08-02: Research Opportunities Soliciting an NSBRI Center of Acute Radiation Research for Ground-Based Studies on Acute Radiation Effects (Due date: May 8, 2008).
RFA-AI-07-040, BARDA/NIAID Medical Countermeasures to Mitigate and/or Treat Ionizing Radiation-Induced Pulmonary Injury: Project Bioshield (RC1) (Due date: March 11, 2008).
RFA-AI-07-037: BARDA/NIAID Medical Countermeasures to Mitigate and/or Treat Ionizing Radiation-Induced Cutaneous Injury: Project Bioshield (RC1) (Due date: March 11, 2008).
RFA-AI-07-038: Radiation Combined Injury: Radiation Exposure in Combination with Burn, Wound, Trauma, or Infection (Phased Innovation Award [R21/R33]) (Due date: Jan. 24, 2008)
RFA-AI-07-039: Mechanisms, Diagnosis, and Treatment of Radiation Injury from a Nuclear Accident or Terrorist Attack (R01) (Due date: Jan. 15, 2008).
RFA-AI-07-036: Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1) (Due date: Jan. 9, 2008).
RFA-AI-07-013: Medical Countermeasures to Restore Gastrointestinal Function after Radiation Exposure: Project Bioshield (RC1) (Due date: April 19, 2007).
NASA Research Announcement (NRA) for Ground-Based Studies in Radiation Biology Solicitation No. NNJ07ZSA001N—External link (Issued Jan. 5, 2007).
Announcement: Biodefense Countermeasure Development: Project Bioshield: Protecting the Immune System Against Radiation (Released July 23, 2004).
Centers for Medical Countermeasures against Radiation—RFA-AI-04-045 (Released Nov. 23, 2004).
Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies: Project BioShield (R01)—RFA-AI-06-030 (Released March 30, 2006).
PA-09-093: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44])
CMCR Public Briefing (Dec. 15, 2004).
RFP-15-100-SOL-00004: BARDA Chem and Rad/Nuc Animal Model Development. Response date: May 4, 2015.
BAA-NIAID-DAIT-NIHAI2014001: Development of Medical Countermeasures to Mitigate and/or Treat Radiation-Induced Lung Injury after a Radiological/Nuclear Incident
BAA-NIAID-DAIT-NIHAI2013166 - Development of Medical Countermeasures to Enhance Platelet Regeneration and Survival Following Radiation Exposure from a Radiological/Nuclear Incident. Due Date July 1, 2013
FDA BAA-12-00118: Food and Drug Administration Broad Agency Announcement for the Advanced Research and Development of Regulatory Science and Innovation. Continuously open announcement valid through May 22, 2013.
BARDA-CBRN-BAA-12-100-SOL-00011: Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medicine Countermeasures
Department of Defense: CHEMICAL AND BIOLOGICAL DEFENSE PROGRAM SBIR 13.1 Proposal Submission – Topic CBD13-108: Rapid biodosimetry for accurate assessment of individual radiation exposure levels (Due Date – January 16, 2013).
BARDA-BAA-11-100-SOL-009: Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures)
PHS 2011-1: Solicitation of NIH and CDC for Small Business Innovation Research (SBIR) Contract Proposals. Research topics identified include: NCI Topic 291 - Radioprotector/Mitigator Development to Decrease Normal Tissue Injury During Radiotherapy. Due Date: Nov. 8, 2010. Download Solicitation Package (PDF).
RFP-NIAID-DAIT-NIHAI2009079: Radiation/Nuclear Medical Countermeasure Product Development Support Services
BAA-NIAID-DAIT-NIHAI2009051: Development of Oral Radionuclide Decorporation Agents for Use in Radionuclide Decorporation in Radiological Emergencies
BAA-NIAID-DAIT-NIHAI2009060: Development of Oral Form of Diethylenetriaminepentaacetate (DTPA) for Use in Radionuclide Decorporation – Radiological Emergency
Issued by the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (BAA-BARDA-09-36): Point of Care of High-Throughput Biological Assays for Determining Absorbed Ionizing Radiation Dose (Biodosimetry) after Radiologic and Nuclear Events.
Issued by the Defense Threat Reduction Agency (DTRA): BAA for Chemical and Biological Technologies Directorate New Initiatives FY2010-FY2011, October 17, 2008. See BAA Amendment 1, Oct. 30, 2008 for Radiation Topics.
Issued by the U.S. Special Operations Command, June 26, 2007: Broad Agency Announcement, Bio-Medical Research Topics.
Defense Threat Reduction Agency’s (DTRA's) Basic Research Program for Combating Weapons of Mass Destruction (WMD) and Basic Research in the Chemical Biological Defense Program. (HDTRA1-07-BRCWMD-BAA. Phase I proposal receipt deadline: June 8, 2007.)
RFP Issued by the U.S. Army Space and Missile Defense Command: Solicitation # W9113M-07-R-0002: To Develop and Deliver in Minimal Time and Minimal Cost, an FDA-Approved Medical Countermeasure for Radiation Injury to Increase Survival following Radiation Exposure (Issued Feb. 16, 2007).
RFP-NIH-NIAID-DAIT-05-46, Development of Improved DTPA for Radionuclide Chelation (Released May 6, 2005).
Draft RFP Issued by the Office of Public Health Emergency Preparedness (HHS): Medical Countermeasures to Mitigate or Treat Neutropenia Associated with Acute Radiation Syndrome (ARS) That Will Support a Public Health Emergency Response to a Radiological or Nuclear Event (RFI-ORDC-05-01A).
Issued April 10, 2007, by the Defense Advanced Research Projects Agency (DARPA): BAA 07-29: Radiation Biodosimetry (RaBid) Announcement.
Issued by the Department of Health and Human Services, May 30, 2007: Therapeutics Applicable for the Treatment of Neutropenia Resulting from Exposure to Ionizing Radiation
Issued by the Department of Defense, CBMS-MITS (Solicitation # W9113M-09-R-0010): Advanced Development of a Medical Radiation Countermeasure (MRC) to treat the Gastrointestinal Subsyndrome of Acute Radiation Syndrome (ARS)
BAA-NIAID-DAIT-NIHAI2012147: Development of Medical Countermeasures to Mitigate or Treat the Gastrointestinal Acute Radiation Syndrome after a Nuclear or Radiation Incident (responses due Nov.15, 2012)
back to top
Last Updated June 15, 2015